J.B. Chemicals reported FY26 standalone net profit of ₹9,027.3 million, up 8.6% YoY, with revenue growing 4.5% to ₹38,898.9 million.
Board recommended a final dividend of ₹9.30 per equity share for FY26 and approved amalgamation with Torrent Pharmaceuticals at 51:100 share exchange ratio.
Exceptional items of ₹27.18 million included severance costs from distribution restructuring and gratuity liability increase from new Labour Code.
Auditors Deloitte issued unmodified opinions on both standalone and consolidated FY26 financial results and clean limited review for Q4 FY26.